Sugi Predict

Sugi Predict / Compounds / SCHEMBL5715243

SCHEMBL5715243

SCHEMBL5715243

Cc1ccc(N2CCN(C(=O)Oc3ccc(C(C)Sc4ncc[nH]4)cc3)CC2)nc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PANK3 Q9H999 5/20 0.52
▸ HRH3 Q9Y5N1 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ CYP1A2 P05177 2/20 0.36
▸ CYP2C9 P11712 2/20 0.36
▸ CYP2C19 P33261 2/20 0.36
▸ OGA O60502 1/20 0.36
▸ GPR119 Q8TDV5 2/20 0.35
▸ KDR P35968 1/20 0.35
▸ ETV6 P41212 1/20 0.35
▸ TRPA1 O75762 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ AOC3 Q16853 1/20 0.35
▸ DRD2 P14416 1/20 0.35
▸ DRD1 P21728 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715494 0.90 PANK3 (0.53) PANK3HRH3SMN1; SMN2OGAKDR
SCHEMBL5715127 0.90 PANK3 (0.51) PANK3HRH3SMN1; SMN2HPGD
SCHEMBL5715048 0.90 PANK3 (0.50) PANK3HRH3SMN1; SMN2CYP1A2CYP2C9
SCHEMBL5716315 0.88 SMN1; SMN2 (0.52) PANK3HRH3SMN1; SMN2HPGDCYP1A2
SCHEMBL5715343 0.87 HSD17B10 (0.49) PANK3HRH3SMN1; SMN2HPGDCYP1A2
SCHEMBL5715669 0.87 PANK3 (0.48) PANK3HRH3SMN1; SMN2HPGDCYP1A2
SCHEMBL5716255 0.85 PANK3 (0.42) PANK3SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL5715377 0.84 TP53 (0.39) PANK3CYP1A2CYP2C9CYP2C19DRD2
SCHEMBL5714359 0.83 PANK3 (0.44) PANK3HRH3SMN1; SMN2HPGDCYP1A2
SCHEMBL5715276 0.82 HRH2 (0.37) PANK3HRH3DRD2DRD1DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 — — US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 — — EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 — — WO claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 — — EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC PANK3 1247/4885HRH3 1098/4885SMN1; SMN2 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.